Vaccine Response With NT-I7
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Carcinoma|Colorectal Adenocarcinoma|Bladder Carcinoma
Interventions: BIOLOGICAL: Recombinant human IL-7-hyFc (NT-I7)|BIOLOGICAL: Vaccine sequence 1|BIOLOGICAL: Vaccine sequence 2
Sponsor: National Cancer Institute (NCI)
Collaborators: NeoImmuneTech